Trade Mark Journal No.2026/046 13 November 2026

UK00004467768 30 October 2026 (5)

AMPOZEOS

International priority date claimed: 15 October 2026 (United States of America) (50163235)

Class 5: Pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy; pharmaceutical preparations for the treatment of primary membranous nephropathy; pharmaceutical preparations for the treatment of lupus nephritis; pharmaceutical preparations for the treatment of renal anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; pharmaceutical preparations for the treatment of immune thrombocytopenia; pharmaceutical preparations for the treatment of immune thrombocytopenia purpura; pharmaceutical preparations for the treatment of cold autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of warm autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of blood diseases and disorders; pharmaceutical preparations for the treatment of inflammation related diseases and disorders.

Vertex Pharmaceuticals Incorporated

Representative: Haseltine Lake Kempner LLP